Dra. Luisa Lilia Rocha Arrieta

Postdoctoral: Department of Neurology. University of California Los Angeles 1989-1992

Ph.D. Pharmacology, Cinvestav. Mexico. 1994

Master: Physiology, Institute of Biomedical Research. UNAM. Mexico. 1988

M.D. School of Medicine, UNAM. Mexico. 19857

Present position: Professor 3E at the Pharmacobiology Department. Center for Research and Advanced Studies. Mexico, D.F. (04/2006-at present).

Level at the National System of Investigators (SNI): III

Topics of investigation:

In our group we focus on analyzing molecular, biochemical and genetic changes in various neurotransmitters in the brain with epilepsy and especially with drug-resistant epilepsy. The purpose is to identify the neurotransmitters responsible for this disorder so we can design new therapeutic strategies to control. They are evaluated neurotransmission systems at the molecular level, since its synthesis, release and synaptic changes at the level of their receptors and transductional downstreams.

Another line of research is the study of new therapeutic strategies to reduce or prevent epileptic activity. Among these strategies is the analysis of the effects of substances with wide use in the market and whose pharmacokinetics, pharmacodynamics and side effects are well known. These substances were previously identified to present potential anticonvulsant effects and are set as new therapeutic use. Another therapeutic strategy represents neuromodulation or brain stimulation to reduce the intensity of seizures. We also focus on identifying nanomaterials whose application is beneficial for patients with drug-resistant epilepsy.

Representative Publications:

*Luna-Munguia, H., Orozco-Suárez. S., Rocha, L. Effects of High Frequency Electrical Stimulation and R-verapamil on seizure susceptibility and Glutamate and GABA release in a model of phenytoin-resistant seizures. Neuropharmacology. 2011; 61(4):807-14.

*Rocha L. Interaction between electrical modulation of the brain and pharmacotherapy to control pharmacoresistant epilepsy. Pharmacol Ther. 2013. Jan 24. pii: S0163-7258(13)00021-1. doi: 10.1016/j.pharmthera.2013.01.009.

*Alcantara-Gonzalez D, Floran B, Escartin E, Rocha L. Changes on D2-like receptor induced Gi protein activation and hippocampal dopamine release in kindled rats. Prog Neuropsychopharmacol Biol Psychiatry. 2013, 40: 246–251.

*Cuellar-Herrera, M., Velasco AL, Velasco F, Trejo D, Alonso-Vanegas M, Nuche-Bricaire A, Vázquez-Barrón D, Guevara-Guzmán R, Rocha L.  Alterations of 5-HT1A receptor-induced G-protein functional activation and relationship to memory deficits in patients with pharmacoresistant temporal lobe epilepsy. Epilepsy Res. 2014, 108: 1853-63.

*Arida RM, Silva SG, de Almeida AA, Cavalheiro EA, Zavala-Tecuapetla C, Brand S, Rocha, L. Differential effects of exercise on brain opioid receptor binding and activation in rats. J. Neurochem. 2015, 132: 206-217.

*Rocha, L., Alonso-Vanegas, M., Martínez-Juárez, I.E., Orozco-Suárez, S., Escalante-Santiago, D., Feria-Romero, I., Zavala-Tecuapetla, C., Cisneros-Franco, J.M., Buentello-García, R.W., Cienfuegos, J. GABAergic alterations in neocortex of patients with pharmacoresistant temporal lobe epilepsy can explain the comorbidity of anxiety and depression: the potential impact of clinical factors. Front. Cell. Neurosci. 2015, 8: 442.

*Santana-Gómez CE, Alcántara-González D, Luna-Munguía H, Bañuelos-Cabrera I, Magdaleno-Madrigal V, Fernández-Mas R, Besio W, Rocha L. Transcranial focal electrical stimulation reduces the convulsive expression and amino acid release in the hippocampus during pilocarpine-induced status epilepticus in rats. Epilepsy & Behav. 2015;49:33-9.

*Di Ianni ME, Enrique AV, Del Valle ME, Aldana B, Rosella MA, Rocha L, Castro EA, Bruno-Blanch LE, Talevi A. Is there a relationship between sweet taste and seizures? Anticonvulsant and proconvulsant effects of non-nutritive sweeteners. Combinatorial Chemistry & High Throughput Screening. 2015;18:335-45

*Valle-Dorado, M.G., Santana-Gómez, C.E., Orozco-Suárez, S., Rocha, L. The mast cell stabilizer sodium cromoglycate reduces histamine release and status epilepticus-induced neuronal damage in the rat hippocampus. Neuropharmacology. 2015, 92:49-55.

*Rosillo-de la Torre A, Zurita-Olvera L, Orozco-Suárez S, Garcia Casillas PE, Salgado-Ceballos H, Luna-Bárcenas G, Rocha L. Phenytoin carried by silica core iron oxide nanoparticles reduces the expression of pharmacoresistant seizures in rats. Nanomedicine (Lond). 2015;10:3563-3577.

*Martínez-Levy GA, Rocha L, Lubin FD, Alonso-Vanegas MA, Nani A, Buentello-García RM, Pérez-Molina R, Briones-Velasco M, Recillas-Targa F, Pérez-Molina A, San Juan Ortra D, Cienfuegos J, Cruz-Fuentes CS. Increased expression of BDNF transcript with exon VI in hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Neuroscience. 2016;314:12-21.

Direction of students

Undergraduate 2
Master in Pharmacology 15
Ph.D. in Pharmacology 9

National committees

-President of the Mexican Society of Physiological Sciences, 2004-2005
-Member of the Awards Commission of the Mexican Academy of Science (2014-2016).
-Commission for Promotion of the Investigators of Cinvestav (2010-2012) (2016-2017).

International committees

-Member of the Neurobiology Committee of the International League Against Epilepsy. (1998-2005)
-Member of the Scientific Committee for the “XX Latinoamerican Congress of Physiological Sciences” (September 2000)
-Member of the Scientific Committee for the “III Latinoamerican Epilepsy Congress” (September 2004)
-Member of the Educational Commission of the International League Against Epilepsy. (2005-)
-President of the Mexican Chapter of the Society for Neuroscience (2009-2011).
-Member of the Committee of Miledi Course (2011-2013)
-Member of the Latino-American Regional Committee of IBRO (LARC-IBRO) (2013-2017).
-Member of the “Task Force for Translational Research” Committee of the International League Against Epilepsy (2014-).

Member of the Following Societies


Laboratory 8

Phone +52(55)5483-2859
Fax +52(55)5483-2863
E-mail: lrocha@cinvestav.mx